Meeting
2022 ASCO Annual Meeting
KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor.
Authors
Steven Bialick
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center, Miami, FL
Steven Bialick , Brandon Edward Rose , Andrea P. Espejo-Freire , Priscila Barreto Coelho , Philippos Apolinario Costa , Leticia Campoverde , Leylah Drusbosky , Junaid Arshad , Cesar Serrano , Suzanne George , Sebastian Bauer , Neha Goel , Shree Venkat , Aditi Dhir , Emily Jonczak , Gina Z. D'Amato , Jonathan C. Trent
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Gastrointestinal Stromal Tumors (GIST)
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 11514)
DOI
10.1200/JCO.2022.40.16_suppl.11514
Abstract #
11514
Poster Bd #
419
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Exploration of drug resistance in advanced gastrointestinal stromal tumor.
First Author: Hao Xu
Poster
2023 ASCO Annual Meeting
Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study.
First Author: Jonathan C. Trent
Poster
2018 ASCO Annual Meeting
A retrospective natural history study of patients (pts) with PDGFRα D842V mutant advanced gastrointestinal stromal tumor (GIST) previously treated with a tyrosine kinase inhibitor (TKI).
First Author: Margaret von Mehren
Poster
2020 ASCO Virtual Scientific Program
Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.
First Author: Suzanne George